FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385279> ?p ?o ?g. }

• W4308385279 abstract "<h3>Background</h3> Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and 5 (CEACAM5, CEA) are members of the carcinoembryonic antigen (CEA) family. CEACAM1 is expressed on a variety of immune cells and acts as a cell–cell communication molecule. The signal transduction process is associated with immune cell activation, apoptosis, proliferation and differentiation. In the pathophysiological stage, CEACAM1 and 5 are dysregulated in various malignancies including, for instance, breast, lung, and gastrointestinal cancer. This seems associated with poor prognosis linked to a novel checkpoint blockade mechanism mediated by homophilic CEACAM1⇔1 and heterophilic CEACAM1⇔5 interaction between immune and tumor cells, respectively. YB-200 is a novel IgG1 antibody targeting CEACAM 1/5, which has shown to preserve the immune agonistic function of CEACAM1 on leukocytes in addition to potentially inhibiting both the homophilic and heterophilic checkpoint blockade of CEACAM1 and 5 on tumor cells. The present study was designed to test the <i>in vivo</i> anti-tumor activity of YB-200 and its effect on immune cells. <h3>Methods</h3> Anti-tumor activity of YB-200 was assessed using the validated ReactionBiology’s SubQperior® experimental syngeneic liver Hepa-1-6 tumor model. The tumor cells were injected into the mammary fat pad of C57BL/6 mice. On Day 5 after tumor cell injection, animals were randomized (median tumor size ~50 mm³) in two groups and treatment started. Mice were treated i.p. BIWx3 with either isotype control or YB-200 at 10 mg/kg/administration. Animals were euthanized on Day 20, and tumors harvested for flow cytometry analysis. Flow cytometry for immune-cell profiling was performed using the ReactionBiology All-in-one® staining panel. <h3>Results</h3> Treatment with YB-200 induced statistically significant tumor growth inhibition by ~80% compared to isotype control, at well-tolerated dose. Flow cytometry analysis revealed that YB-200 led to a 10-fold increase in B-cells in the tumor micro-environment compared to the isotype control. In addition, a statistically significant increase in CD3+ and CD4+ T-cells was observed while granulocytes decreased. <h3>Conclusions</h3> This study demonstrates that treatment with YB-200 induced statistically significant tumor growth inhibition compared to isotype control in a validated hepatocellular carcinoma model. Consistent with the role of CEACAM1 as cell-cell communication molecule the anti-tumor activity of YB-200 was correlated with a strong modulation of the immune cell compartment in the tumor micro environment. <h3>Ethics Approval</h3> This animal study has been approved by the Ethics Committee for Animal Experimentation and is registered by the regional board Freiburg, Germany. Mice were handled according to the German animal welfare law and the GV-SOLAS guidelines." @default.
• W4308385279 created "2022-11-11" @default.
• W4308385279 creator A5034848616 @default.
• W4308385279 creator A5061881249 @default.
• W4308385279 creator A5074049671 @default.
• W4308385279 creator A5083439873 @default.
• W4308385279 creator A5086250043 @default.
• W4308385279 date "2022-11-01" @default.
• W4308385279 modified "2023-09-25" @default.
• W4308385279 title "1384 Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment" @default.
• W4308385279 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1384" @default.
• W4308385279 hasPublicationYear "2022" @default.
• W4308385279 type Work @default.
• W4308385279 citedByCount "0" @default.
• W4308385279 crossrefType "proceedings-article" @default.
• W4308385279 hasAuthorship W4308385279A5034848616 @default.
• W4308385279 hasAuthorship W4308385279A5061881249 @default.
• W4308385279 hasAuthorship W4308385279A5074049671 @default.
• W4308385279 hasAuthorship W4308385279A5083439873 @default.
• W4308385279 hasAuthorship W4308385279A5086250043 @default.
• W4308385279 hasBestOaLocation W43083852791 @default.
• W4308385279 hasConcept C121608353 @default.
• W4308385279 hasConcept C126322002 @default.
• W4308385279 hasConcept C147483822 @default.
• W4308385279 hasConcept C159654299 @default.
• W4308385279 hasConcept C16224149 @default.
• W4308385279 hasConcept C203014093 @default.
• W4308385279 hasConcept C2776090121 @default.
• W4308385279 hasConcept C2776107976 @default.
• W4308385279 hasConcept C2777387746 @default.
• W4308385279 hasConcept C2777701055 @default.
• W4308385279 hasConcept C2779256057 @default.
• W4308385279 hasConcept C2780851360 @default.
• W4308385279 hasConcept C502942594 @default.
• W4308385279 hasConcept C71924100 @default.
• W4308385279 hasConcept C8891405 @default.
• W4308385279 hasConceptScore W4308385279C121608353 @default.
• W4308385279 hasConceptScore W4308385279C126322002 @default.
• W4308385279 hasConceptScore W4308385279C147483822 @default.
• W4308385279 hasConceptScore W4308385279C159654299 @default.
• W4308385279 hasConceptScore W4308385279C16224149 @default.
• W4308385279 hasConceptScore W4308385279C203014093 @default.
• W4308385279 hasConceptScore W4308385279C2776090121 @default.
• W4308385279 hasConceptScore W4308385279C2776107976 @default.
• W4308385279 hasConceptScore W4308385279C2777387746 @default.
• W4308385279 hasConceptScore W4308385279C2777701055 @default.
• W4308385279 hasConceptScore W4308385279C2779256057 @default.
• W4308385279 hasConceptScore W4308385279C2780851360 @default.
• W4308385279 hasConceptScore W4308385279C502942594 @default.
• W4308385279 hasConceptScore W4308385279C71924100 @default.
• W4308385279 hasConceptScore W4308385279C8891405 @default.
• W4308385279 hasLocation W43083852791 @default.
• W4308385279 hasOpenAccess W4308385279 @default.
• W4308385279 hasPrimaryLocation W43083852791 @default.
• W4308385279 hasRelatedWork W3029687374 @default.
• W4308385279 hasRelatedWork W3039388108 @default.
• W4308385279 hasRelatedWork W3108853735 @default.
• W4308385279 hasRelatedWork W3153709335 @default.
• W4308385279 hasRelatedWork W3177607563 @default.
• W4308385279 hasRelatedWork W4206354376 @default.
• W4308385279 hasRelatedWork W4224222365 @default.
• W4308385279 hasRelatedWork W4285731353 @default.
• W4308385279 hasRelatedWork W4304979265 @default.
• W4308385279 hasRelatedWork W4378715746 @default.
• W4308385279 isParatext "false" @default.
• W4308385279 isRetracted "false" @default.
• W4308385279 workType "article" @default.